| HOME >> MEDICINE >> TECHNOLOGY |
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET 147
P2Y12 IS A PROVEN TARGET FOR MULTIPLE
INDICATIONS; APPROVALS ARE EXPECTED 147
PLAVIX METABOLIZER 2C19 TRIGGERS US WARNING 147
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENSION 148
VALTURNA FIRST TO RECEIVE US APPROVAL AS
COMBINATION THERAPY FOR HYPERTENTION 149
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS,
IN PARTICULAR FACTOR XA 150
APOB-100 AS A NOVEL TREATMENT FOR
HYPERLIPIDEMIA 151
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH
HDL CHOLESTEROL LEVELS 151
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT 152
TABLE 65 MARKET VALUE OF RECENTLY APPROVED DRUGS,
2009-2015 ($ MILLIONS) 153
TABLE 66 SUMMARY PIPELINE FORECAST, 2009-2015 ($ MILLIONS) 153
INDUSTRY STRUCTURE 153
TABLE 67 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH
AND SHARE, THROUGH 2010 ($ MILLIONS) 154
MARKET TRENDS 155
TABLE 68 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS,
THROUGH 2015 ($ MILLIONS) 156
Massive Patent Expiration is a Growth Opportunity for
Generics 156
Market Expansion via Disease Prevention is the Future of
Cardio Care 157
Atrial Fibrillation is a Large and Emerging Disease State 157
Atrial Fibrillation … (Continued) 158
Combination Therapies are Synergistic Revenue
Generators 159
PIPELINE ANALYSIS 160
TABLE 69 APPROVED PRODUCT FORECAST, 2010 AND 2015 ($
MILLIONS) 160
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT 160
2010 APPROVALS IN CARDIOVASCULAR THERAPY 161
MULTAQ (DRONEDARONE): SANOFI-AVENTIS 161
TABLE 70 MULTAQ SNAPSHOT 161
XARELTO (RIVAROXABAN): BAYER SCHERING/J&J 162
TABLE 71 XARELTO SNAPSHOT 163
EFFIENT/EFIENT (PRASUGREL): ELI LILLY/DAIICHI
SANKYO 164
TABLE 72 EFFIENT SNAPSHOT 164
RENDIX (DABIGAT
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |